NEWS
SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer
SciSparc (Nasdaq: SPRC) announced that its venture, MitoCareX Bio , has validated the potential significant involvement of its target SLC25 carrier protein in Non-Small Cell Lung Cancer (NSCLC) cells. The discovery was demonstrated using genetic manipulations and 3D spheroid systems, mimicking human solid tumors. NSCLC, accounting for 80%-85% of all lung cancer cases globally, is projected to reach a market value of $59.77 billion by 2030.
MitoCareX previously screened millions of small molecules using its proprietary MITOLINE™ algorithm, identifying potential anti-cancer treatments. The company is now working on creating a predictive AI model to more efficiently discover novel anti-cancer small molecule scaffolds targeting its SLC25 protein of interest.
MitoCareX previously screened millions of small molecules using its proprietary MITOLINE™ algorithm, identifying potential anti-cancer treatments. The company is now working on creating a predictive AI model to more efficiently discover novel anti-cancer small molecule scaffolds targeting its SLC25 protein of interest.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1667Followers
93Following
13KVisitors
Follow